renal cell protection of erythropoietin beyond correcting the anemia in chronic kidney disease patients

Renal Cell Protection of Erythropoietin beyond Correcting The Anemia in Chronic Kidney Disease Patients

Currently many patients with chronic renal failure have profited from the use of erythropoietin to correct anemia (1,2). In chronic kidney disease, anemia is believed to be a surrogate index for tissue hypoxia that continues preexisting renal tissue injury (1-3). Erythropoietin is an essential glycoprotein that accelerates red blood cell maturation from erythroid progenitors and facilitates ery...

the impact of human recombinant erythropoietin on renal function in patients with chronic kidney disease

Treatment of Anemia in Chronic Kidney Disease: Beyond EPo

Anemia is associated with serious and irreversible complications including cardiac disease and has been shown to increase the risk of mortality. Anemia causes decrease exercise capacity, cognitive impairment and poor quality of life. Anemia has also been implicated in the development of left ventricular hypertrophy and congestive heart failure. Correction of anemia in patients with CKD, prolong...

The role of indoxyl sulfate in renal anemia in patients with chronic kidney disease

Renal anemia is a common complication in patients with advanced chronic kidney disease. In vitro studies have shown that indoxyl sulfate decreases erythropoietin production. Whether this effect is seen in vivo remains unclear. Our goal was to explore the role of indoxyl sulfate in renal anemia. We found serum indoxyl sulfate levels are significantly and negatively associated with erythropoietin...

Pharmacologic Adjuvants to Reduce Erythropoietin Therapy Dose in Anemia of Chronic Kidney Disease and End Stage Renal Disease

Anemia is one of the leading causes of morbidity in chronic renal failure.1 Chronic kidney disease (CKD) associated anemia is largely due to reduced erythropoietin (EPO) release and, to a lesser degree, to shortened red cell survival.2 To overcome EPO deficiency in this population, the development and administration of erythropoiesis-stimulating agents (ESAs) such as recombinant human EPO and d...

Anemia of chronic kidney disease.

A nemia is a common complication in patients with chronic kidney disease (CKD). Recombinant erythropoietin (epoetin) has been the most important advance in treating this anemia. Erythropoietin was approved by the Food and Drug Administration (FDA) in 1989. Although the initial goal of treating CKD anemia with epoetin was to prevent blood transfusions, evidence from prospective studies also demo...